Experimental Hematology and Oncology

SJR Rank #413H-index: 58SJR: 4.126Best quartile: Q1Open AccessAPC: US$3,290Listed in DOAJ
Journal website: aims, scope and author guidelines
Publisher

BioMed Central Ltd

Country

United Kingdom

Type

journal

SJR by Edition

2022202502468

Subject Categories

  • Cancer ResearchQ1
  • HematologyQ1
  • OncologyQ1

Areas: Biochemistry, Genetics and Molecular Biology · Medicine

Most published research topics

CAR-T cell therapy researchAcute Myeloid Leukemia ResearchCancer Immunotherapy and BiomarkersLymphoma Diagnosis and TreatmentImmune Cell Function and InteractionImmunotherapy and Immune ResponsesImmune cells in cancerMultiple Myeloma Research and TreatmentsAcute Lymphoblastic Leukemia researchChronic Lymphocytic Leukemia Research

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs085170255340

Documents per Year

2022202503570105140

Detailed Information

ISSN

2162-3619

SJR Best Quartile

Q1

Region

Western Europe

Citations per Document (2 years)

10.49

References per Document

84.62

Coverage

2012-2026

Scope

Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings. Experimental Hematology & Oncology publishes original work, hypothesis, commentaries and timely reviews. With open access and rapid turnaround time from submission to publication, the journal strives to be a hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the closely related fields of hematology and oncology.

Metrics from SCImago Journal Rank 2025. View on SCImago